GlassScriptPhysician profile
Craig J Vine
NPI 1164400495
$136,362.06
in general payments reported to CMS, 2019-2025
20 companies · $439 in 2025
The $439 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31K · 2020: $3,329 · 2021: $11K · 2022: $40K · 2023: $35K · 2024: $17K · 2025: $439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $32K · Consulting Fee: $14K · Travel and Lodging: $3,862 · Food and Beverage: $2,483.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $31,640.00 |
| Consulting Fee | $13,500.00 |
| Travel and Lodging | $3,862.44 |
| Food and Beverage | $2,483.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $71,723.78 | 2019-2024 | Ingrezza |
| Alkermes, INC. | $42,631.52 | 2021-2025 | Lybalvi, Aristada, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $14,052.46 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $5,045.61 | 2019-2025 | Invega Sustenna |
| Neuronetics, INC. | $1,262.29 | 2019-2025 | Neurostar Tms Therapy System |
| Livanova USA, INC. | $1,109.37 | 2019-2025 | Vns Therapy Symmetry Model 8103 Generator |
| Tempus Ai, INC | $114.46 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $90.87 | 2021-2025 | Caplyta |
| Lundbeck LLC | $62.54 | 2020-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $42.66 | 2019-2025 | Fanapt |
| Corium, LLC | $41.34 | 2023-2024 | Azstarys |
| Almatica Pharma LLC | $40.86 | 2021-2025 | Loreev Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $32.73 | 2022-2024 | Trintellix |
| Eisai INC. | $32.02 | 2020 | |
| Tris Pharma INC | $16.02 | 2023 | Dyanavel Xr |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $15.11 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $13.72 | 2025 | Cobenfy |
| Abbvie INC. | $12.20 | 2022 | |
| Jazz Pharmaceuticals INC. | $11.36 | 2021 | |
| Allergan, INC. | $11.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Vine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.